Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: A genome-wide association and polygenic scoring study
Epidemiological studies have recognized a genetic diathesis for suicidal behavior, which is independent of other psychiatric disorders. Genome‐wide association studies (GWAS) on suicide attempt (SA) and ideation have failed to identify specific genetic variants. Here, we conduct further GWAS and for...
Saved in:
Published in | American journal of medical genetics. Part B, Neuropsychiatric genetics Vol. 165B; no. 5; pp. 428 - 437 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.07.2014
Wiley Subscription Services, Inc BlackWell Publishing Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Epidemiological studies have recognized a genetic diathesis for suicidal behavior, which is independent of other psychiatric disorders. Genome‐wide association studies (GWAS) on suicide attempt (SA) and ideation have failed to identify specific genetic variants. Here, we conduct further GWAS and for the first time, use polygenic score analysis in cohorts of patients with mood disorders, to test for common genetic variants for mood disorders and suicide phenotypes. Genome‐wide studies for SA were conducted in the RADIANT and GSK‐Munich recurrent depression samples and London Bipolar Affective Disorder Case‐Control Study (BACCs) then meta‐analysis was performed. A GWAS on suicidal ideation during antidepressant treatment had previously been conducted in the Genome Based Therapeutic Drugs for Depression (GENDEP) study. We derived polygenic scores from each sample and tested their ability to predict SA in the mood disorder cohorts or ideation status in the GENDEP study. Polygenic scores for major depressive disorder, bipolar disorder and schizophrenia from the Psychiatric Genomics Consortium were used to investigate pleiotropy between psychiatric disorders and suicide phenotypes. No significant evidence for association was detected at any SNP in GWAS or meta‐analysis. Polygenic scores for major depressive disorder significantly predicted suicidal ideation in the GENDEP pharmacogenetics study and also predicted SA in a combined validation dataset. Polygenic scores for SA showed no predictive ability for suicidal ideation. Polygenic score analysis suggests pleiotropy between psychiatric disorders and suicidal ideation whereas the tendency to act on such thoughts may have a partially independent genetic diathesis. © 2014 The Authors. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics published by Wiley Periodicals, Inc. |
---|---|
Bibliography: | Institute of Psychiatry, King's College London GlaxoSmithKline G0701420 istex:C04B64115B413DE9256EFFE024BE271AFF580875 Maudsley NHS Foundation Trust Medical Research Council, UK The National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London ArticleID:AJMGB32247 German Federal Ministry of Education and Research European Commission Framework 6 ark:/67375/WNG-3LN9441B-S ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 How to Cite this Article: Mullins N, Perroud N, Uher R, Butler AW, Cohen-Woods S, Rivera M, Malki K, Euesden J, Power RA, Tansey KE, Jones L, Jones I, Craddock N, Owen MJ, Korszun A, Gill M, Mors O, Preisig M, Maier W, Rietschel M, Rice JP, Müller-Myhsok B, Binder EB, Lucae S, Ising M, Craig IW, Farmer AE, McGuffin P, Breen G, Lewis CM. 2014. Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: A genomewide association and polygenic scoring study. Grant sponsor: Medical Research Council, UK; Grant sponsor: GlaxoSmithKline G0701420; Grant sponsor: The National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London; Grant sponsor: Maudsley NHS Foundation Trust; Grant sponsor: Institute of Psychiatry, King's College London; Grant sponsor: German Federal Ministry of Education and Research; Grant sponsor: European Commission Framework 6. Conflict of interest: Farmer and McGuffin have received consultancy fees and honoraria for participating in expert panels for pharmaceutical companies, including GlaxoSmithKline. Ising has received consultancy honoraria from MSD Merck. Binder has received grant support from PharmaNeuroboost. Lewis has received consultancy honoraria from Eli Lilly. All other authors declare no conflicts of interest. |
ISSN: | 1552-4841 1552-485X 1552-485X |
DOI: | 10.1002/ajmg.b.32247 |